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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs (containing about 22 nucleotides) that regulate gene expression.
MiRNAs are involved in many different biological processes such as cell proliferation, differentiation, apoptosis, fat
metabolism, and human cancer genes; while miRNAs may function as candidates for diagnostic and prognostic
biomarkers and predictors of drug response. This paper emphasizes the statistical methods in the analysis of the
associations of miRNA gene expression with human cancers and related clinical phenotypes: 1) simple statistical
methods include chi-square test, correlation analysis, t-test and one-way ANOVA; 2) regression models include linear
and logistic regression; 3) survival analysis approaches such as non-parametric Kaplan-Meier method and log-rank
test as well as semi-parametric Cox proportional hazards models have been used for time to event data; 4) multivariate
method such as cluster analysis has been used for clustering samples and principal component analysis (PCA) has
been used for data mining; 5) Bayesian statistical methods have recently made great inroads into many areas of science,
including the assessment of association between miRNA expression and human cancers; and 6) multiple testing.
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Background
A microRNA (miRNA) is a small non-coding RNA molecule
(containing about 22 nucleotides), which functions in RNA silencing
and post-transcriptional regulation of gene expression [1-3]. MiRNAs
are involved in many different biological processes such as cell
proliferation, differentiation, apoptosis, fat metabolism, and human
cancer genes [4-8]. Previous studies suggest that miRNAs expression
profiles are correlated with disease pathogenesis and prognosis, and
may ultimately be useful in the management of human cancer; while
miRNAs may function as candidates for diagnostic and prognostic
biomarkers and predictors of drug response. For example, miRNAs
can act either as oncogenes or tumor suppressors contributing to
initiation and progression of cancer [3,6,9-12]. MiRNA expression
can be detected by a two-step polymerase chain reaction process of
RT-PCR followed by quantitative PCR [13], microarray [14], and
miRNA sequencing [15]. The raw counts of miRNA expression are
usually skewed and not meet the assumptions of parametric statistical
tests, therefore a log2 transformation is applied [16,17], for example
by a weighted trimmed mean of the log expression ratios using the R/
Bioconductor package [18,19].

Simple Statistical Methods
Some studies examined the miRNA expression level as a categorical
variable, which was dichotomized as low and high level expression
based on the median [20-22]. The chi-square test has been used to
determine the associations of expression of miRNA-21 with patients’
clinical parameters such as lymph node metastasis, clinical stage and
poor prognosis in non-small cell lung cancer (NSCLC) as categorical
variables [22]. This approach was also used to test the relationship
between miRNA-221 expression and binary clinicopathologic features
such as histology, p-TNM stage and history of smoking [23]; and the
correlation between miRNA-124 down-regulates SOX8 expression
and binary clinicopathologic factors such as tumor size, lymph node
metastasis, differentiation classification and clinical stage [24].
However, most other studies treated the miRNA expression as
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a continuous variable. For example, the t-test for two-independent
samples has been used to compare the expression values of miRNAs
between the control and lung cancer groups [17,25], the expression
of miRNA-146 in NSCLC cancer tissue (43 individuals) and normal
tissue (32 individuals) [26]. Furthermore, the t-test for paired samples
was performed to identify if miRNA-31 is differentially expressed
between lung adenocarcinoma and matched normal adjacent tissues
using the Cancer Genome Atlas (TCGA) dataset [27]. Moreover, oneway ANOVA was utilized to examine the association between E2F
miRNA expression and degree of tumor cell invasion in gastric cancer
[28]. Additionally, non-parametric methods such as Wilcoxon signrank test for paired samples analysis was used to compare expression
of miRNAs across the seven tumor samples in breast cancer [29] and
Kruskal-Wallis test was used to determine the significance of miRNAs
among the biochemical failure categories [30].
The simple correlation analysis has been used to describe the
relationship of miRNA expression with cancer clinical phenotypes.
For example, the correlation between miRNA-148a expression and the
methylation level of the DNA region encoding miRNA-148a in tissues was
evaluated by Pearson’s correlation [31]. Other studies used the Spearman's
rank correlation analysis to correlate miRNAs with mRNA in the breast
cancer samples [32], the alterations of methylation with expression level
of miRNA-9-1 gene in the lung tumors [33], and the pairwise miRNA
expression in seven types of cancer using the TCGA data [34].

Linear and Logistic Regression Models
The linear and logistic regression models have been used to
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examine the associations of miRNA expression with cancer and clinical
phenotypes. For example, linear regression analysis was used to identify
the association of 335 miRNAs with recurrent ovarian cancer cell lines
[35] and to examine the association between cigarettes per day in lung
cancer patients and miRNA expression [36]. Recently, a multiple linear
regression analysis was used to investigate the associations of each
mRNA transcript with the corresponding miRNAs in colorectal cancer
[37].
The binary logistic regression analysis was utilized to select the top
25 miRNA genes with prognostic relevance in neuroblastoma, that
is, the miRNAs with the lowest P-value in a model testing miRNA
expression levels (below or above the median expression) versus overall
survival [38], evaluate the ability of chosen miRNAs to distinguish
between breast cancer cases and controls [39], and differentially
expressed genes that are regulated by the mRNAs expression between
gastric cancer and paired adjacent normal tissues [28]. Multiple logistic
regression analyses have been performed to investigate the role of
miRNA signature on binary outcomes in neuroblastoma such as cases
defined as relapse, progression, or death from disease (progressionfree survival), and death (overall survival) comparing with controls
defined as nonfailure in the first 3 years of follow-up, adjusted for age
at diagnosis, stage and other phenotypes [38]. Another study used a
multiple logistic model of specific miRNA biomarkers to predict the
presence of menstrual blood [40]. Recently, Zhang et al. [41] evaluated
the associations of both human papillomavirus-HPV16 status and
IL-1α rs3783553 polymorphism at the miRNA-122 binding site,
individually and in combination, with the risk of oral squamous cell
carcinoma (OSCC) using both univariate and multivariable logistic
regression analyses.

Survival Analysis
The non-parametric Kaplan-Meier method has been used to
estimate the survival distributions for expression of miRNA-21 [42],
miRNA-148a [31], miRNA-31 [27], miRNA-221 [23], and miRNA-124
in NSCLC [24]; while the log-rank test has been used to analyze
the survival differences according to expression between different
subgroups [23,24,27,31,42]. Recently, the Kaplan-Meier method
was used to estimate the overall survival curves for four miRNAs
(miRNA-21, 22, 155 and 210) in the TCGA glioblastoma multiforme
dataset using the BRB-Array Tools - R/BioConductor [16]. Another
recent study used the Kaplan-Meier survival analysis to estimate the
survival distributions for patients in each of 5 subtypes of glioblastoma
multiforme based on significant miRNAs and applied the log-rank test
to assess the statistical significance between the stratified high- and
low-risk survival groups in primary glioblastoma in the TCGA dataset
using GraphPad Prism 6.0 statistical software [43].
The semi-parametric Cox proportional hazards model has been
widely used to construct respective prognostic miRNA signatures of
cancers [21,22,27,42,43]. For example, multivariable Cox proportional
hazards model was used to identify the significant influence of miRNA148a expression on survival, adjusted for gender, age, histologic grade, T
stage and smoking status [31]. Another study used the univariable Cox
regression analysis to examine the association between 9 continuous
miRNA expression and overall survival rate of Glioblastoma Multiforme
(GBM) using the TCGA dataset; while multivariable Cox regression
analysis was performed by stratifying patients according to age and
using MGMT methylation status, IDH1 mutations, pre-treatment,
recurrence, and TCGA prognostic classification as covariates [16].
Especially, Mankoo et al. [44] implemented a multivariate Cox Lasso
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model and median time-to-event prediction algorithm and applied it
to two datasets integrated from the four genomic data types (mRNA,
DNA methylation, DNA copy-number alteration and miRNA) in the
TCGA data.

Multivariate Methods
Multivariate analysis methods such as cluster analysis has been
used for clustering samples, and principal component analysis
(PCA) has been used for data mining. For example, to identify
miRNA expression patterns in breast cancer, one study performed
an unsupervised hierarchical complete linkage cluster analysis using
Euclidean distance as dissimilarity metric; meanwhile a Pearson χ2 test
and a Goeman global test were used to investigate the association of
the sample clustering result with clinicopathological variables [32,45].
Keller et al. [25] analyzed the abundance of 904 miRNAs in serum from
eight cancer patients at three time points and from six healthy control
individuals and identified clusters based on the identified miRNA
signatures, hierarchical clustering and a self-organizing map; while
Oberg et al. [46] used PCA and hierarchical cluster analyses to visualize
miRNA expression patterns present at a global level in colon cancer.
Another study applied a complete linkage hierarchical clustering using
the Euclidian distance to compute the dissimilarity of miRNA and
samples independently of each other using the normalized data [17].
In addition, Li et al. [21] identified an eight-miRNA (miR-31, miR196b, miR-766, miR-519a-1, miR-375, miR-187, miR-331 and miR101-1) signature for the prediction of overall survival of patients with
lung adenocarcinoma (LUAD) using supervised principal components
method in the TCGA-derived LUAD cohort.

Bayesian Statistics
Bayesian statistical methods have recently made great inroads into
many areas of science [47], including the assessment of association
between miRNA expression and human cancers. One of the main
challenges in modeling the statistical dependence between highthroughput studies is that a large number of measurements (usually in
thousands) is available for a relatively small number (usually in tens or
hundreds) of patient samples; therefore, classical statistical approaches
based on linear models and hierarchical clustering are prone to overfitting [48,49]. In these situations, Efron [48] recommended accounting
for high-dimensionality by using approaches that borrow information
across covariates to compensate for the limited information available
across samples, which leads to better and more reliable inference.
Several approaches have been developed to address these challenges
in various contexts, for example hierarchical Bayesian modeling
approaches based on linear shrinkage estimators [50]. For predicting
relevant clinical outcomes, Srivastava et al. [51] proposed a flexible
statistical machine learning approach that acknowledges and models
the interaction between platform-specific measurements through
nonlinear kernel machines and borrows information within and
between platforms through a hierarchical Bayesian framework. The
methods of integrating gene/mRNA expression and miRNA profiles
for predicting patient survival times were applied to the TCGA based
glioblastoma multiforme (GBM) dataset [51]. Recently, Chekouo et al.
[52] proposed a novel Bayesian model to identify miRNAs and their
target genes that were associated with survival time by incorporating
the miRNA regulatory network through prior distributions.

Multiple Testing
The number of miRNA in human genome is abundant and multiple
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outcomes have been measured in many miRNA expression studies.
Therefore, the multiple testing issue is a big statistical challenge.
The conservative Bonferroni correction (0.05/n, n is the number of
tested miRNA) has been used for dealing with multiple testing [53].
Furthermore, the false discovery rate (FDR) based on the Benjamini
and Hochberg method [54] was used to correct multiple testing in
comparison of miRNA expression levels across different groups [5557]. Additionally, some studies have used permutation tests to account
for multiple testing in comparison of miRNA expression profile, for
example, by using 1,000 or 10,000 permutations [36,43,53].

Discussion and Future Direction
The t-test and one-way ANOVA require the assumption of
normality of the data; however, such assumption is often violated in
practice. Therefore, generalized linear models (GLMs) and generalized
linear mixed models (GLMMs) can relax the assumption and deal
with binary and counts data. For example, GLMMs can be used to
compare the miRNA measures before/after or with/without treatment.
Furthermore, non-parametric statistical methods may be alternatives
in some specific situations to describe the miRNA data with cancer.
In survival analysis, many studies have focused on non-parametric
methods such as Kaplan-Meier method and log-rank test and semiparametric Cox proportional hazards models. Non-parametric
methods have the advantages of no assumptions for the underlying
survival distributions; while Cox model made certain assumptions
about the nature of hazard function for proportional hazards regression
method. In practice, it can be assumed that the survival function is of a
certain form such as exponential, Weibull, and so on, with one or more
parameters whose values are unknown, to be estimated from real data
[58]. Furthermore, if the shape of the survival distribution is known,
parametric regression models may produce more efficient estimates
than Cox model [59].
Till now, the sample sizes used in miRNA expression studies are
relatively small, therefore, Bayesian methods may have some advantages
in flexibility and for incorporating information from previous studies.
Future studies with large sample sizes will be required to increase
the power in detection of the significance and also for adjusting for
multiple covariates in regression models. In addition, due to the
complex correlation structure between multiple tests, adjusting for
multiple testing is a big statistical challenge but is essential in analysis
of miRNA expression with human cancers.
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